Holding(s) in Company

Dechra Pharmaceuticals PLC
12 January 2024
 

veTR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009633180

Issuer Name

DECHRA PHARMACEUTICALS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Bank of America Corporation

City of registered office (if applicable)

 

Country of registered office (if applicable)

US

4. Details of the shareholder

Name

City of registered office

Country of registered office

Merrill Lynch International

London

United Kingdom

5. Date on which the threshold was crossed or reached

10-Jan-2024

6. Date on which Issuer notified

11-Jan-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.285272

1.845725

9.130997

10400742

Position of previous notification (if applicable)

6.901602

1.878360

8.779962


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB0009633180


8298354


7.285272

Sub Total 8.A

8298354

7.285272%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Right to Recall

N/A

N/A

16991

0.014917

Physical Swaps

03/06/2024

N/A

966106

0.848162

Sub Total 8.B1


983097

0.863079%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Swaps

17/04/2024

N/A

Cash

437610

0.384186

Swaps

31/07/2024

N/A

Cash

324556

0.284933

Swaps

08/11/2024

N/A

Cash

20000

0.017558

Swaps

18/11/2024

N/A

Cash

1904

0.001672

Swaps

02/12/2024

N/A

Cash

10000

0.008779

Swaps

17/12/2024

N/A

Cash

243780

0.214019

Swaps

18/12/2024

N/A

Cash

41053

0.036041

Swaps

23/12/2024

N/A

Cash

33840

0.029709

Swaps

30/12/2024

N/A

Cash

1745

0.001532

Swaps

02/01/2025

N/A

Cash

1129

0.000991

Swaps

03/02/2025

N/A

Cash

496

0.000435

Swaps

04/02/2025

N/A

Cash

258

0.000227

Swaps

06/05/2025

N/A

Cash

2920

0.002564

Sub Total 8.B2


1119291

0.982646%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Bank of America Corporation

Bank of America, National Association




Bank of America Corporation

Merrill Lynch International

6.932924


7.376157%

Bank of America Corporation

BofA Securities Europe SA




10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

11-Jan-2024

13. Place Of Completion

United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings